City
Epaper

Bharat Biotech slashes Covaxin's price from ₹600 to ₹400 per dose for states

By Lokmat English Desk | Updated: April 29, 2021 18:15 IST

Hyderabad-based vaccine manufacturer Bharat Biotech on Thursday slashed the price of its indigenous Covid-19 vaccine candidate 'Covaxin' to ₹400 ...

Open in App

Hyderabad-based vaccine manufacturer Bharat Biotech on Thursday slashed the price of its indigenous Covid-19 vaccine candidate 'Covaxin' to ₹400 per dose for state government to procure it. Earlier, the company had kept the price at ₹600 for one dose. The reduction in Covaxin's price for states comes just a day after Serum Institute of India also reduced Covishield prices by 25% to ₹300.On price reduction of Covaxin, Bharat Biotech said, "Recognising the enormous challenges to the public health care system, we have made Covaxin available to state government at ₹400 per dose".

"We wish to be transparent in our approach to pricing which was determined by internally funded product development, several operationally-intensive BSL-3 manufacturing facilities, and clinical trial," it added. Eariler, central government had asked Bharat Biotech to lower the price of their Covid-19 vaccines amid criticism from several states who have accused the companies of profiteering from the crisis. Hyderabad-based Bharat Biotech previously  fixed the price of Covaxin at Rs 600 per dose for state governments, and Rs 1,200 per dose for private hospitals. The Centre has also relaxed its vaccination strategy in the third phase of the mass inoculation programme, under which everyone above the age of 18 will be eligible for a shot from May 1.In the new vaccine regime, manufacturers will supply 50 per cent of their monthly Central Drugs Laboratory (CDL)-released doses to the central government, and will be free to supply the remaining 50 per cent to state governments and the open market.

 

Tags: Bharat Biotech InternationalCoronavirusCoronavirus Vaccine
Open in App

Related Stories

TechnologyNew Covid Wave Could Peak by August-End in South Korea; Government Strengthens Response Measures

HealthCOVID-19: Only 2% of Patients Develop Autoantibodies After Recovery, Study Reveals

HealthAfter Covishield, BHU Study Reveals Side Effects of Covaxin; Including Hair Loss, Skin Issues, and Menstrual Irregularities

InternationalAstraZeneca Withdraws COVID-19 Vaccine Globally Days After Side Effect Row, Firm Says Decision ‘Commercial’

HealthGood News! Scientists Develop All-in-One Vaccine Effective Against Current and Future Coronavirus Variants

Health Realted Stories

HealthShingles vaccine can protect heart health up to 8 years: Study

HealthStudy shows HIV prevalence rising in older adults, but prevention focusses youth

HealthJharkhand govt to withdraw order removing RIMS Director, HC disposes of petition

HealthElderly dementia patients in S. Korea hold assets worth 6.4 pc of GDP: Report

HealthHere’s how Ayurveda tourism is redefining wellness travel